United States Patent 7,691,880: Scope, Claim Coverage, and US Landscape for Oral Methylphenidate HCl Solutions
US Drug Patent 7,691,880 claims a storage-stable oral solution of methylphenidate HCl formulated with (i) an organic acid in defined concentration, and (ii) a defined multi-solvent system defined by water, at least one polyol, and at least one glycol, with optional conventional additives.
What is the claimed invention in one line?
An oral methylphenidate HCl solution with specified drug load (0.1–10 mg/mL), specified organic acid loading (0.5–5 mg/mL in Claim 1; narrower ranges in dependent claims), and a defined solvent system of water + polyol(s) + glycol(s) that yields storage stability.
No claim covers salts other than methylphenidate HCl or alternative dosage forms (tablets, suspensions, films) on the face of the asserted claim set provided.
What is the core independent claim scope (Claim 1) and what does it cover?
Claim 1: Independent scope
Oral methylphenidate HCl solution comprising:
- Methylphenidate HCl: about 0.1 mg/mL to about 10.0 mg/mL
- Organic acid: about 0.5 mg/mL to about 5.0 mg/mL, “at least one”
- Solvent system comprising:
- Water: about 10% to about 45%
- Polyol solvent: about 30% to about 70%
- Glycol solvent: about 10% to about 70%
- Storage stable (functional limitation)
Coverage character (Claim 1):
- Ingredient-flexible on organic acid identity (broad “at least one organic acid” in Claim 1).
- Ingredient-flexible on polyol identity and glycol identity (broad classes).
- Formulation-anchored by the ratio windows (water/polyol/glycol) and the presence of organic acid at defined concentration.
- Functional requirement: stability is part of the claim, meaning a challenger must address whether the accused formulation meets “storage stable” under the patent’s definition (not provided in the prompt).
Key numerical boundaries
The independent claim creates three simultaneous constraints:
- Drug concentration: 0.1–10 mg/mL
- Organic acid: 0.5–5 mg/mL
- Solvent system composition:
- Water: 10–45%
- Polyol: 30–70%
- Glycol: 10–70%
(These ranges do not state that they sum to 100% in the prompt, but they are written as “comprising” ranges that typically are intended to cover the bulk vehicle.)
How do dependent claims narrow the scope (and what alternate design-arounds exist)?
Claim 2 (Organic acids are limited to a listed set)
Organic acid selected from:
- acetic acid, ascorbic acid, citric acid, fumaric acid, malic acid, succinic acid, tartaric acid, and mixtures.
Effect: Claim 1 is broader; Claim 2 is a species claim. If an accused formulation uses a different acid not in the list, it may avoid Claim 2 but still potentially fall under Claim 1 if that different acid still fits “at least one organic acid” (Claim 1 is not limited to this list in the prompt).
Claims 3–4 (Polyol and glycol solvent identity)
- Claim 3: polyol solvent selected from glycerin, sorbitol, sucrose, fructose, and mixtures.
- Claim 4: glycol solvent selected from propylene glycol, polyalkylene glycol products, and mixtures.
These are class restrictions. If a competitor uses a polyol outside the list (e.g., xylitol is not listed), it may avoid Claims 3 while still potentially falling under Claim 1 (since Claim 1 uses “at least one polyol solvent” without restricting the species list in the prompt).
Claim 5 (Optional additives)
Further including one or more conventional pharmaceutical additives:
- flavorings, colorants, buffers, preservatives, and mixtures.
Effect: Because Claim 5 is optional (“further including”), the presence or absence of these additives does not narrow the baseline. A formulation need not include them to infringe Claim 1 or Claim 6–15 as written in the prompt; it only matters for Claim 5.
What are the alternative independent claim pathways (Claims 6 and 11)?
Claim 6: Alternative independent composition window
Oral methylphenidate HCl solution comprising:
- Methylphenidate HCl: about 0.1 to 10 mg/mL
- Organic acid: about 0.5 to 3.0 mg/mL
- Solvent system:
- Water: 10–45%
- Polyol: 40–60%
- Glycol: 10–30%
- Storage stable
Effect: Claim 6 is narrower than Claim 1 in both:
- Organic acid max reduced to 3.0 mg/mL
- Glycol window reduced to 10–30%
- Polyol window tightened to 40–60%
- Water range stays 10–45%.
Claim 11: Third independent window
Oral methylphenidate HCl solution comprising:
- Methylphenidate HCl: about 0.1 to 10 mg/mL
- Organic acid: about 0.5 to 1.5 mg/mL
- Solvent system:
- Water: 30–40%
- Polyol: 45–55%
- Glycol: 10–20%
- Storage stable
Effect: Claim 11 pushes to a mid-water and tighter vehicle composition, with the lowest acid ceiling among the independent claims.
Why these multiple independent claims matter
They create overlapping yet distinct vehicle envelopes:
- Claim 1 is the broadest solvent-space (widest polyol and glycol ranges, and highest acid ceiling at 5.0 mg/mL).
- Claim 6 targets formulations with moderate-to-high polyol and lower glycol and an acid ceiling at 3.0 mg/mL.
- Claim 11 targets highly specific water/polyol/glycol balance and acid ceiling at 1.5 mg/mL.
What species claims are present in Claims 12–15?
- Claim 12: organic acid includes citric acid
- Claim 13: polyol includes glycerin
- Claim 14: glycol includes polyethylene glycol
- Claim 15: further including pharmaceutical additives (flavorings, colorants, buffers, preservatives, mixtures)
These are “platform” species anchors within the Claim 11 framework.
What is the likely infringement test structure for an accused product?
On the face of the claims provided, an infringement assessment turns on four checkpoints:
-
Oral methylphenidate HCl solution
- Must be a liquid solution (not suspension or gel) delivering methylphenidate HCl.
-
Drug concentration
- Falls within 0.1–10 mg/mL in each independent claim.
-
Organic acid concentration
- Must fall within the specific ranges:
- Claim 1: 0.5–5.0 mg/mL
- Claim 6: 0.5–3.0 mg/mL
- Claim 11: 0.5–1.5 mg/mL
-
Vehicle composition
- Must fall within one of the solvent windows (Claim 1 vs Claim 6 vs Claim 11) with defined water + polyol + glycol percentage ranges.
-
“Storage stable”
- This is functional. If storage stability is measured by the patent’s test conditions (not provided in the prompt), the product must meet the same performance expectation.
How defensible is the claim breadth vs typical methylphenidate liquid formulations?
Given the claim structure, the breadth is driven by two flexibilities:
- Organic acid identity flexibility in Claim 1 (“at least one organic acid”) and vehicle flexibility in polyol/glycol selection (as classes).
- Large numerical ranges in Claim 1 for vehicle components (water 10–45%, polyol 30–70%, glycol 10–70%).
But the breadth is constrained by:
- Acid concentration caps, especially in Claims 6 and 11.
- Glycol and polyol windows, especially in Claims 6 and 11.
- The “storage stable” functional limitation, which can be an enforcement bottleneck unless the patent provides an objective stability definition in the specification.
What does the US patent landscape likely look like around this claim theme?
Without the actual publication record, family members, specification, or prosecution history for US 7,691,880 in the prompt, only the claim theme can be mapped: acid-preserved, polyol/glycol vehicle oral solution of methylphenidate HCl.
Landscape by “technology axis” (not by exact citations)
-
Methylphenidate base drug patents (composition-of-matter, crystalline forms, salts)
- These usually have earlier priority and are generally not the direct fit for a formulation-vehicle claim focused on stability and excipients.
-
Oral liquid formulation patents
- Common blocks in this space include:
- aqueous vehicles,
- humectants (polyols),
- co-solvents (glycols),
- pH adjustment / stabilization via organic acids,
- flavoring and preservatives.
-
Stability-driven excipient selection patents
- Claims often converge on:
- organic acid type,
- defined excipient concentration windows,
- specific vehicle ratios to reduce degradation and preserve shelf-life.
In this patent, the enforceable novelty sits at the intersection of:
- organic acid concentration window
- specific multi-solvent ratio (water + polyol + glycol)
- storage stability
What design-arounds are suggested by the claim architecture?
Based on the provided claim numeric windows:
Avoiding Claim 1 while targeting Claims 6/11 (or vice versa)
- If an accused formulation uses organic acid concentration above 5.0 mg/mL it is outside Claim 1 but may still fall outside Claims 6 and 11 (all have lower maxima).
- If it uses glycol outside 10–70% (Claim 1) or outside tighter windows in Claims 6/11, it may avoid all independent claims.
- If it uses water below 10% or above 45% (or outside 30–40% in Claim 11), it can exit the vehicle envelope for one or more claims.
Avoiding species-dependent claims (2, 3, 4, 12–14)
- Use a non-listed organic acid to avoid Claims 2 and 12.
- Use a polyol outside glycerin/sorbitol/sucrose/fructose to avoid Claim 3 and the glycerin-inclusion requirement in Claim 13.
- Use a glycol type outside propylene glycol/polyalkylene glycol products or avoid polyethylene glycol to avoid Claims 4 and 14.
But this does not necessarily avoid Claim 1 because Claim 1 uses generic “at least one organic acid/polyol/glycol solvent” classes in the prompt.
Enforcement leverage and claim dependency
The claim set you supplied is structured so that:
- Independent claims (1, 6, 11) cover the vehicle framework and stability.
- Dependent claims (2–5, 7–10, 12–15) add ingredient identity constraints and additive presence.
In litigation posture, independent claims typically drive infringement. Dependent claims matter for:
- narrowing during claim construction,
- secondary infringement theories if an accused product matches a specific acid/polyol/glycol species.
Key Takeaways
- US 7,691,880 claims a storage-stable oral methylphenidate HCl solution defined by drug loading (0.1–10 mg/mL), organic acid concentration windows, and a three-component solvent system (water + polyol + glycol) with defined ratio ranges.
- The patent contains three independent claim “vehicle envelopes”: Claim 1 (broadest), Claim 6 (tighter glycol and polyol ranges; acid max 3.0 mg/mL), and Claim 11 (tightest with water 30–40% and acid max 1.5 mg/mL).
- Dependent claims lock in specific acids (citric, acetic, etc.), polyols (glycerin, sorbitol, sucrose, fructose), and glycols (propylene glycol, polyalkylene glycol, polyethylene glycol) plus optional additives like flavorings and preservatives.
- Practical coverage hinges on whether an accused formulation’s acid mg/mL and vehicle percentages land inside one of the independent claim envelopes, and whether it meets the “storage stable” limitation under the patent’s test conditions.
FAQs
1) Does the patent cover tablets or only liquids?
The claims are directed to an oral methylphenidate HCl solution, which is a liquid formulation, not a solid dosage form.
2) Is citric acid required for infringement?
No. Citric acid is only explicitly required in dependent Claim 12. Claim 1 and Claim 6 cover “at least one organic acid” in the specified concentration ranges.
3) What is the maximum organic acid concentration?
Across independent claims:
- 5.0 mg/mL in Claim 1
- 3.0 mg/mL in Claim 6
- 1.5 mg/mL in Claim 11
4) Can a competitor avoid the patent by changing polyol identity?
Changing polyol identity can avoid dependent Claims 3 and 13, but it may still fall within Claim 1 if the new polyol still qualifies as “at least one polyol solvent” within the vehicle ranges.
5) What is the most important vehicle constraint for designing around?
The most controllable constraint is the water/polyol/glycol percentage windows in the independent claims, especially the narrower glycol 10–30% (Claim 6) and 10–20% (Claim 11) envelopes.
References
[1] US Patent 7,691,880 (claims as provided in prompt).
